S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AUTL Autolus Therapeutics PLC

4.19

0.08 (1.95%)

May 03 2024 - Closed

Delayed by 15 minutes

Licensing Option Exercise Sends Shares Higher

A London-based biotech company caught the attention of traders on Wednesday after it was announced that Moderna Inc.

To read the full story on AllPennyStocks.com, click here.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics PLC News

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Tuesday 23 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

Autolus Therapeutics Announces Changes to its Board of Directors
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.

Autolus Therapeutics announces publication in Blood Cancer Journal
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Autolus Therapeutics announces publication in Nature Communications
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13D - General statement of acquisition of beneficial ownership
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

More Autolus Therapeutics PLC News Articles

Bell Buckle (PK)

Umbra Applied Technologies (PK)

Marketing Worldwide (PK)

Code Green Apparel (PK)

Moon Equity (PK)

Cann American (CE)

Digital Brand Media and ... (PK)

Intergrated Cannabis Sol... (PK)

AMC Entertainment

1812 Brewing (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions